1.
|
Phase: Phase IV
Type: Supportive care, Treatment
Status: Active
Age: 18 to 75
Sponsor: NIMH
Protocol IDs: R01 MH071580, DATR A3-NSS, NCT00352885
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 75 and under
Sponsor: Other
Protocol IDs: CNR-9506, EU-95024, NCT00002702
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 15 to 60
Sponsor: Other
Protocol IDs: EORTC-06991, NCT00004128, GIMEMA-EORTC-06991
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 30 and under at diagnosis
Sponsor: NCI
Protocol IDs: COG-ANBL0032, ANBL0032, COG-P9842, NCT00026312
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 75
Sponsor: Other
Protocol IDs: BRD/04/1-D, NCT00200577
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: A/100/0402, NCT00477906
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: WSU-2006-130, NCT00027807, RWMC-0635146, WSU-010307M1F, WSU-0312004412
|
|
8.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 75 and under
Sponsor: NCI
Protocol IDs: FHCRC-1655.00, 5430, NCT00052520
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 20 to 75
Sponsor: Other
Protocol IDs: 27MD02, NCT00154713
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: pepDCIL2- HMO-CTIL, NCT00279058
|
|
11.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UR0414, NCT00197860
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MM0413, NCT00197912
|
|
13.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CPRL002A2201, NCT00414765
|
|
14.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UMN-2007LS064, UMN-2007LS064, MT2007-12, UMN-0707M13561, NCT00625729
|
|
15.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: FHCRC-2225.00, FHCRC-2225.00, IR-6881, BMS-CA184-062, NCT00871481
|
|
16.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 to 75
Sponsor: NCI
Protocol IDs: FHCRC-2355.00, FHCRC-2355.00, IR-6984, NCT01005537
|
|
17.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 090092, 09-C-0092, NCT00923390
|
|
18.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 090047, 09-C-0047, NCT00923806
|
|
19.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 070210, 07-C-0210, NCT00924001
|
|
20.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 090082, 09-C-0082, NCT00924326
|
|
21.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI
Protocol IDs: FHCRC-2271.00, FHCRC-2271.00, IR-6982, NCT00945269
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-99-C-0158, NCI-T99-0078, T99-0078, NCT00019942
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 70
Sponsor: Other
Protocol IDs: 271296-HMO-CTIL, NCT00149006
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: 1747CTIL, Raphael Rubinov, NCT00226798
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IL-2-LOK-MM, NCT00204581
|
